دورية أكاديمية
أعرض في EDS

SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome.

التفاصيل البيبلوغرافية
العنوان: SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome.
المؤلفون: Kanduc D; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy.
المصدر: Global medical genetics [Glob Med Genet] 2022 Jul 14; Vol. 9 (3), pp. 191-199. Date of Electronic Publication: 2022 Jul 14 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Thieme Country of Publication: Germany NLM ID: 101769583 Publication Model: eCollection Cited Medium: Internet ISSN: 2699-9404 (Electronic) Linking ISSN: 26999404 NLM ISO Abbreviation: Glob Med Genet Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Stuttgart] : Thieme, [2020]-
مستخلص: Background  Contrary to immunological expectations, decay of adaptive responses against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) characterizes recovered patients compared with patients who had a severe disease course or died following SARS-CoV-2 infection. This raises the question of the causes of the virus-induced immune immunosuppression. Searching for molecular link(s) between SARS-CoV-2 immunization and the decay of the adaptive immune responses, SARS-CoV-2 proteome was analyzed for molecular mimicry with human proteins related to immunodeficiency. The aim was to verify the possibility of cross-reactions capable of destroying the adaptive immune response triggered by SARS-CoV-2. Materials and Methods  Human immunodeficiency-related proteins were collected from UniProt database and analyzed for sharing of minimal immune determinants with the SARS-CoV-2 proteome. Results  Molecular mimicry and consequent potential cross-reactivity exist between SARS-CoV-2 proteome and human immunoregulatory proteins such as nuclear factor kappa B (NFKB), and variable diversity joining V(D)J recombination-activating gene (RAG). Conclusion  The data (1) support molecular mimicry and the associated potential cross-reactivity as a mechanism that can underlie self-reactivity against proteins involved in B- and T-cells activation/development, and (2) suggest that the extent of the immunosuppression is dictated by the extent of the immune responses themselves. The higher the titer of the immune responses triggered by SARS-CoV-2 immunization, the more severe can be the cross-reactions against the human immunodeficiency-related proteins, the more severe the immunosuppression. Hence, SARS-CoV-2-induced immunosuppression can be defined as a molecular mimicry syndrome. Clinically, the data imply that booster doses of SARS-CoV-2 vaccines may have opposite results to those expected.
Competing Interests: Conflict of Interest None declared.
(The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).)
References: BMJ. 2021 Nov 24;375:e067873. (PMID: 34819275)
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515. (PMID: 30395287)
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):156-161. (PMID: 34283655)
Future Microbiol. 2015;10(4):503-15. (PMID: 25865190)
Front Biosci (Schol Ed). 2012 Jun 01;4(4):1393-401. (PMID: 22652881)
Blood. 2006 Feb 1;107(3):1048-55. (PMID: 16195333)
J Immunol. 2021 Aug 15;207(4):1150-1164. (PMID: 34341167)
J Immunol. 1998 Jul 1;161(1):90-6. (PMID: 9647211)
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519)
Protein Pept Lett. 2019;26(7):542-549. (PMID: 30950342)
Immunity. 2003 Jun;18(6):763-75. (PMID: 12818158)
Am J Hum Genet. 2015 Sep 3;97(3):389-403. (PMID: 26279205)
Nat Genet. 2012 Jan 29;44(3):291-6. (PMID: 22286218)
F1000Res. 2019 Feb 4;8:. (PMID: 30800289)
J Exp Med. 1998 Jan 19;187(2):147-59. (PMID: 9432973)
Clin Immunol. 2018 Oct;195:49-58. (PMID: 30063981)
Clin Infect Dis. 2021 Dec 16;73(12):2366-2368. (PMID: 33693643)
J Clin Invest. 2020 Oct 1;130(10):5235-5244. (PMID: 32634129)
J Immunol. 2009 Aug 15;183(4):2205-12. (PMID: 19661265)
Immunity. 1996 Jul;5(1):73-9. (PMID: 8758896)
Vaccines (Basel). 2021 Dec 31;10(1):. (PMID: 35062724)
Glob Med Genet. 2021 Jun 26;8(4):162-170. (PMID: 34877574)
Am J Hum Genet. 2013 Nov 7;93(5):812-24. (PMID: 24140114)
Nat Commun. 2021 Jul 29;12(1):4678. (PMID: 34326343)
Bioinformatics. 2013 Nov 1;29(21):2808-9. (PMID: 23958731)
Cell. 2021 Jan 21;184(2):476-488.e11. (PMID: 33412089)
Mol Cells. 2021 Jun 30;44(6):392-400. (PMID: 34059562)
J Allergy Clin Immunol. 2013 Feb;131(2):477-85.e1. (PMID: 23374270)
Expert Rev Proteomics. 2021 Mar;18(3):177-184. (PMID: 33825594)
J Virol. 2013 Jan;87(1):482-8. (PMID: 23097434)
EMBO J. 2002 Oct 1;21(19):5184-94. (PMID: 12356734)
Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674)
J Autoimmun. 2021 Nov;124:102713. (PMID: 34390919)
Nat Rev Immunol. 2022 Jan;22(1):57-65. (PMID: 34876702)
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7573-7. (PMID: 8356059)
J Clin Invest. 2010 Jan;120(1):214-22. (PMID: 20038800)
Sci Immunol. 2020 Dec 7;5(54):. (PMID: 33288645)
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24384-24391. (PMID: 32913053)
AIDS Res Hum Retroviruses. 2002 Oct 10;18(15):1141-4. (PMID: 12402950)
Front Pediatr. 2021 Apr 30;9:615724. (PMID: 33996677)
J Immunol. 1996 Nov 15;157(10):4464-73. (PMID: 8906823)
Lancet Healthy Longev. 2022 Jan;3(1):e13-e21. (PMID: 34935001)
Mol Immunol. 2007 Jul;44(15):3724-31. (PMID: 17512595)
J Biol Chem. 2006 May 5;281(18):12699-704. (PMID: 16478731)
Curr Protein Pept Sci. 2013 Mar;14(2):111-20. (PMID: 23305312)
J Clin Virol. 2021 Mar;136:104765. (PMID: 33636554)
J Allergy Clin Immunol. 2010 Apr;125(4):778-87. (PMID: 20371392)
Pathobiology. 2020;87(4):268-276. (PMID: 32726789)
J Immunol. 2019 Jun 15;202(12):3349-3358. (PMID: 31043477)
Blood. 2001 Jan 1;97(1):81-8. (PMID: 11133745)
J Pept Sci. 2012 Aug;18(8):487-94. (PMID: 22696298)
J Exp Med. 2012 Oct 22;209(11):1907-17. (PMID: 23027925)
Trends Microbiol. 2016 Jun;24(6):490-502. (PMID: 27012512)
Immunology. 2020 Oct;161(2):139-147. (PMID: 32615639)
Reprod Biomed Online. 2003 Mar;6(2):154-6. (PMID: 12675989)
J Clin Immunol. 2020 Nov;40(8):1093-1101. (PMID: 32813180)
Clin Transl Immunology. 2021 Mar 04;10(3):e1259. (PMID: 33728049)
EClinicalMedicine. 2021 Jun;36:100902. (PMID: 34056568)
PLoS Comput Biol. 2013;9(6):e1003088. (PMID: 23754940)
Eur J Intern Med. 2021 Dec;94:105-107. (PMID: 34742628)
Sci Rep. 2021 Dec 1;11(1):23216. (PMID: 34853374)
Future Virol. 2019 Apr;14(4):237-246. (PMID: 32201499)
Science. 1990 Jun 22;248(4962):1517-23. (PMID: 2360047)
J Virol Methods. 2021 Dec;298:114295. (PMID: 34555429)
N Engl J Med. 2006 May 4;354(18):1901-12. (PMID: 16672701)
N Engl J Med. 2020 Sep 10;383(11):1085-1087. (PMID: 32706954)
Sci Rep. 2021 Feb 10;11(1):3455. (PMID: 33568776)
Antibodies (Basel). 2020 Jul 16;9(3):. (PMID: 32708525)
Vaccines (Basel). 2021 Oct 08;9(10):. (PMID: 34696253)
Nature. 1989 Feb 16;337(6208):651-3. (PMID: 2465495)
Viruses. 2020 Dec 04;12(12):. (PMID: 33291713)
فهرسة مساهمة: Keywords: NFKB; SARS-CoV-2; V(D)J RAG proteins; cross-reactivity; immunosuppression; molecular mimicry
تواريخ الأحداث: Date Created: 20220718 Latest Revision: 20220719
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9282940
DOI: 10.1055/s-0042-1748170
PMID: 35846107
قاعدة البيانات: MEDLINE
الوصف
تدمد:2699-9404
DOI:10.1055/s-0042-1748170